Ropivacaine + Tramadol — Competitive Intelligence Brief

Ropivacaine + Tramadol (Ropivacaine + Tramadol) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic + opioid analgesic combination. Area: Pain Management / Anesthesia.

marketed Local anesthetic + opioid analgesic combination Voltage-gated sodium channels (ropivacaine); mu-opioid receptor, norepinephrine transporter, serotonin transporter (tramadol) Pain Management / Anesthesia Small molecule

Target snapshot

Ropivacaine + Tramadol (Ropivacaine + Tramadol) — Aga Khan University. Ropivacaine blocks sodium channels to provide local anesthesia, while tramadol inhibits monoamine reuptake and activates opioid receptors to provide analgesia.

Comparator set (4 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ropivacaine + Tramadol TARGET	Ropivacaine + Tramadol	Aga Khan University	marketed	Local anesthetic + opioid analgesic combination	Voltage-gated sodium channels (ropivacaine); mu-opioid receptor, norepinephrine transporter, serotonin transporter (tramadol)
Bupivacaine-fentanyl emergency group	Bupivacaine-fentanyl emergency group	Conrad Arnfinn Bjørshol	marketed	Local anesthetic + opioid analgesic combination	Voltage-gated sodium channels (bupivacaine); mu opioid receptor (fentanyl)
bucain + fentanyl	bucain + fentanyl	University of Debrecen	marketed	Local anesthetic + opioid analgesic combination	Voltage-gated sodium channels (bucain); mu-opioid receptor (fentanyl)
L-BUPIVACAINE ; MORPHINE	L-BUPIVACAINE ; MORPHINE	Corporacion Parc Tauli	phase 3	Local anesthetic + opioid analgesic combination	Voltage-gated sodium channels (L-bupivacaine); mu-opioid receptor (morphine)
Lidocaine 1% Injectable Solution, Sufentanil	Lidocaine 1% Injectable Solution, Sufentanil	University of Saskatchewan	phase 3	Local anesthetic + opioid analgesic combination	Voltage-gated sodium channels (lidocaine); mu-opioid receptor (sufentanil)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic + opioid analgesic combination class)

1. Aga Khan University · 1 drug in this class
2. Conrad Arnfinn Bjørshol · 1 drug in this class
3. Corporacion Parc Tauli · 1 drug in this class
4. University of Debrecen · 1 drug in this class
5. University of Saskatchewan · 1 drug in this class